. 2011 Nov;164(6):1722–1737. doi: 10.1111/j.1476-5381.2011.01483.x

Table 1.

The effects of celecoxib and retigabine (RTG) on the voltage-dependent activation and activation and deactivation kinetics of K_v7 currents

		K_v7.1	K_v7.2	K_v7.3	K_v7.4	K_v7.3/K_v7.5	K_v7.2/K_v7.3	K_v7.2(A235T)	K_v7.2(W236L)
ΔV_1/2 (mV)	Celecoxib (10 µM)	−5.7 ± 1.6	−13.8 ± 0.9^**	−7.8 ± 0.9^**	−20.4 ± 4.2^**	−7.8 ± 2.9^**	−11.5 ± 2.1^**	+32.3 ± 4.9^**	−4.0 ± 3.2
		NS							NS
	RTG (10 µM)	−2.1 ± 1.0	−40.0 ± 1.0^**	−37.9 ± 2.1^**	−27.3 ± 3.1^**	−8.7 ± 2.5^**	−35.6 ± 2.8^**	−7.6 ± 5.1^*	−3.0 ± 8.7
		NS							NS
τ (activation) (ms)	Control	255 ± 18	119 ± 6	77 ± 5	98 ± 17	121 ± 13	60 ± 5
	Celecoxib (10 µM)	318 ± 26^**	103 ± 6^*	58 ± 5^**	93 ± 15	105 ± 11^**	49 ± 3^**
					NS
τ (deactivation) (ms)	Control	208 ± 15	48 ± 2	124 ± 5	60 ± 4	120 ± 16	40 ± 2
	Celecoxib (10 µM)	311 ± 16^**	73 ± 5^**	159 ± 9^**	90 ± 6^**	166 ± 21^**	64 ± 4^**

P < 0.05

^**

P < 0.01 compared with the control

NS, not significant compared with the control.ΔV_1/2– the difference of the half-activation potential before and after treatment with celecoxib or retigabine, ΔV_1/2 = V_1/2 (after) − V_1/2 (before).

n = 4–6 for ΔV_1/2 measurements; n = 5–6 for τ measurements.